Abstract
A cohort study examining data from six countries found that rates of antipsychotic prescribing for patients with dementia increased substantially following the earliest phase of the COVID‐19 pandemic. Antipsychotic prescribing rates did not return to pre‐pandemic levels following the acute phase of the COVID‐19 crisis, the investigators found. Study results were published online Jan. 25, 2023, in JAMA Psychiatry.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
